Sun Pharma cuts US Medicaid drug prices

Sun Pharmaceutical Industries has agreed to lower prices for several of its drugs supplied to US state Medicaid programs. The agreement is part of a federal Most Favoured Nation (MFN) plan announced by former President Donald Trump, which includes nine global pharmaceutical manufacturers.

Analysts and industry experts state the financial impact on India's largest drug maker will likely be minimal. This is due to nuances around the specific portfolio of products affected and the already heavily discounted nature of the Medicaid channel. The company itself views the agreement positively, noting it recognizes Sun Pharma's US investment by delaying tariffs on innovative products for over two years.

Analysts See Limited Financial Impact

Vishal Manchanda, a pharma analyst at Systematix Group, provided an initial estimate. "Based on the Medicaid exposure and assuming a 20-50% price reduction in that channel, we estimate the potential impact at around $20-30 million," he said. He added that the actual impact could be lower as the detailed terms remain confidential.

Another unnamed analyst suggested the potential impact could be in the low single digits, around 1% of earnings, and would not materially alter the overall investment thesis for Sun Pharma. The US market contributes approximately 27% to Sun Pharma's global revenue.

Why the Impact is Expected to be Minimal

A senior analyst from a leading brokerage explained the limited scope. While Sun Pharma generates roughly 27% of its revenue from the US, they estimate less than 10-15% of its specialty portfolio is linked to Medicaid. Medicaid is a joint federal and state program offering health insurance to low-income Americans.

Importantly, Medicaid already operates at a significant discount compared to private channels. Soorya N Patra, a pharma analyst at Phillip Capital, elaborated on this point. "This segment is a very deep-discount segment already. It is usually a 30-40% kind of discounted segment already." Patra said.

Further complexities could limit the effect. Vishal Manchanda of Systematix noted that key Sun Pharma drugs like Ilumya for plaque psoriasis, and newer launches Leqselvi and Unloxcyt, are not sold in Europe. The MFN model aims to align US prices with those in other developed nations, but without a European price for benchmarking, Sun Pharma's exposure differs from companies with an established European presence.

Sun Pharma is a major player in the US dermatology market, ranking second by prescriptions. Its key brands and recent launches are detailed below.

US Manufacturing Investment Commitments

According to a White House fact sheet, the nine companies signing the MFN agreements have collectively committed to invest at least $19.6 billion in US manufacturing in the near term. Several companies, including Sun Pharma, are also donating active pharmaceutical ingredients (APIs) to the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR). This aims to reduce reliance on foreign nations and ensure emergency supplies.

Sun Pharma will contribute 71.4 tonnes of the antibiotic clindamycin and 6.75 tonnes of the antibiotic doxycycline to the SAPIR. The agreement coincides with Sun Pharma's pursuit of its $11.75 billion acquisition of US drug maker Organon, reinforcing its long-term US growth strategy. Sun Pharma shares ended the day following the announcement 1.3% lower on the Bombay Stock Exchange.